Leap Therapeutics Inc (LPTX)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Leap Therapeutics Inc today and set a price target of $12.50. The company’s shares closed yesterday at $8.42.
“We maintain our Buy rating of Leap Therapeutics and our 12-month price target of $12.50 per diluted share. We derive our price target based on a risk-adjusted NPV analysis of projected DKN-01 and TRX518 revenues through 2030 assuming a 12% discount rate and 2% terminal growth rate. We derive an rNPV of $632M for the products and add in pro forma cash and cash equivalents of $40.5M to arrive at a 12-month price target of $12.49 per diluted share, which we round to $12.50.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 7.9% and a 40.7% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
Leap Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $12.75.
Omeros Corp (OMER)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Omeros Corp today and set a price target of $34. The company’s shares closed yesterday at $21.16.
“Valuation methodology, risks and uncertainties. We ascribe a total firm value of roughly $2B to Omeros based on OMIDRIA ($806M) and OMS721 ($1.18B). This translates into a target of $34.00 per share, based on 58M fully-diluted shares outstanding as of end-1Q 2019.”
According to TipRanks.com, Selvaraju is a 2-star analyst with an average return of 0.6% and a 42.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Omeros Corp is a Strong Buy with an average price target of $27.25, implying a 28.8% upside from current levels. In a report issued on July 12, Seaport Global also initiated coverage with a Buy rating on the stock with a $30 price target.
Fate Therapeutics (FATE)
H.C. Wainwright analyst Edward White assigned a Hold rating to Fate Therapeutics today and set a price target of $12. The company’s shares closed yesterday at $10.87.
According to TipRanks.com, White is a top 100 analyst with an average return of 27.9% and a 57.6% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
Currently, the analyst consensus on Fate Therapeutics is a Moderate Buy with an average price target of $16.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.